Promoted Content
Promoted Content

Find Drugs for Infections and Infectious Diseases in Phase III Clinical Development in UNITED KINGDOM

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Azithromycin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 25, 2021

            Details:

            The independent Trial Steering Committee concluded that both azithromycin and doxycycline are generally ineffective against early-stage COVID-19 in patients over 50 who are treated with either antibiotic at home.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Interferon Beta-1A

            Therapeutic Area: Infections and Infectious Diseases Product Name: SNG001

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2021

            Details:

            First patient has been dosed in the UK as part of its global Phase III trial (SG018) evaluating Synairgen’s inhaled formulation of interferon beta-1a (SNG001), for the treatment of hospitalised COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 23, 2020

            Details:

            COV001 is a blinded, multi-centre, randomised, controlled Phase I/II trial assessing safety, immunogenicity and efficacy of AZD1222 in 1,077 healthy adults in five trial centres in the UK.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 08, 2020

            Details:

            Results of an interim analysis of the Phase III programme of AZD1222, demonstrated that the vaccine is safe and effective at preventing symptomatic COVID-19 and that it protects against severe disease and hospitalisation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2020

            Details:

            Researchers show overall vaccine (ChAdOx1 nCoV-19) efficacy of 70.4% from a pooled analysis of two-dose regimen. Efficacy results are based on data taken from 11,636 volunteers across the U. K and Brazil.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RSVPreF3

            Therapeutic Area: Infections and Infectious Diseases Product Name: GSK3888550A

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2020

            Details:

            Patient dosing has begun in a phase 3 clinical programme investigating the safety and efficacy of its Respiratory Syncytial Virus candidate vaccine for maternal immunisation (GSK3888550A), after presentation of positive phase 1/2 safety, reactogenicity and immunogenicity data.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19,Paracetamol

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: University of Oxford

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2020

            Details:

            One dosing regimen showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen showed 62% efficacy when given as two full doses at least one month apart.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cabotegravir,Tenofovir Disoproxil Fumarate,Emtricitabine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Vocabria

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 17, 2020

            Details:

            The breakthrough therapy designation is based on efficacy and safety results from HPTN 083, a phase IIb/III clinical trial that compared long-acting, injectable cabotegravir to daily oral emtricitabine/tenofovir disoproxil fumarate 200 mg and 300 mg for HIV prevention.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cabotegravir,Tenofovir Disoproxil Fumarate,Emtricitabine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020